- Home
- ITOS vs ATYR Comparison
ITOS vs ATYR Comparison
Compare ITOS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- ATYR
- Stock Information
- Founded
- ITOS 2011
- ATYR 2005
- Country
- ITOS United States
- ATYR United States
- Employees
- ITOS N/A
- ATYR N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITOS Health Care
- ATYR Health Care
- Exchange
- ITOS Nasdaq
- ATYR Nasdaq
- Market Cap
- ITOS 271.1M
- ATYR 228.1M
- IPO Year
- ITOS 2020
- ATYR 2015
- Fundamental
- Price
- ITOS $7.41
- ATYR $3.77
- Analyst Decision
- ITOS Strong Buy
- ATYR Strong Buy
- Analyst Count
- ITOS 3
- ATYR 4
- Target Price
- ITOS $21.33
- ATYR $19.25
- AVG Volume (30 Days)
- ITOS 512.7K
- ATYR 797.3K
- Earning Date
- ITOS 11-12-2024
- ATYR 11-07-2024
- Dividend Yield
- ITOS N/A
- ATYR N/A
- EPS Growth
- ITOS N/A
- ATYR N/A
- EPS
- ITOS N/A
- ATYR N/A
- Revenue
- ITOS $35,000,000.00
- ATYR $235,000.00
- Revenue This Year
- ITOS $271.18
- ATYR N/A
- Revenue Next Year
- ITOS N/A
- ATYR $1,200.54
- P/E Ratio
- ITOS N/A
- ATYR N/A
- Revenue Growth
- ITOS N/A
- ATYR N/A
- 52 Week Low
- ITOS $7.09
- ATYR $1.38
- 52 Week High
- ITOS $18.75
- ATYR $3.80
- Technical
- Relative Strength Index (RSI)
- ITOS 36.39
- ATYR 68.54
- Support Level
- ITOS $7.09
- ATYR $3.28
- Resistance Level
- ITOS $7.53
- ATYR $3.51
- Average True Range (ATR)
- ITOS 0.37
- ATYR 0.24
- MACD
- ITOS -0.02
- ATYR 0.03
- Stochastic Oscillator
- ITOS 21.28
- ATYR 98.75
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.